Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TB-100,GT-00AxIL15
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Glycotope
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The combination of Therabest’s iPSC derived NK cell therapy TB-100 and Glycotope’s tumor-targeted immuno-cytokine GT-00AxIL15 challenges the current NK cell therapy paradigm by converging a two-component platform improves the activity of TB-100.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 13, 2022
Lead Product(s) : TB-100,GT-00AxIL15
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Glycotope
Deal Size : Inapplicable
Deal Type : Inapplicable